Pura Vida is a healthcare-focused hedge fund with a market-neutral approach. Since inception, the firm has generated superior returns and was named Best Emerging Manager in Global Equities by Absolute Return in 2018. Pura Vida invests across the healthcare space, including medical technology and devices, biotechnology, pharmaceuticals, and healthcare services.
Location: United States, New York
Employees: 11-50
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Subversive | subversive... |
Mentions in press and media 7
| Date | Title | Description |
| 28.07.2024 | The Resurgence of Private Equity and Health Tech Investments | The world of finance is like a tide. It ebbs and flows, sometimes revealing treasures, sometimes hiding them. Recently, the tide has turned, bringing a wave of activity in private equity and health technology investments. The recent acquisi... |
| 28.07.2024 | The Race for Healthcare Investment: A New Era in Medical Capital | The healthcare landscape is shifting. Private equity firms are circling like hawks, eyeing lucrative investments in medical institutions. The Asian Institute of Medical Sciences (AIMS) in Faridabad is the latest prize. With a valuation of ₹... |
| 26.07.2024 | Imperative Care closes potential $150M Series E and more digital health fundings | Photo: Anchiy/Getty Images Medical technology company Imperative Care announced it initially closed an oversubscribed Series E financing round led by Ally Bridge Group. The company says additional closings of the round could bring its Serie... |
| 27.02.2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| 20.02.2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission ... |
| 15.02.2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know: – Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| 29.07.2021 | Exo Raises $220M to Commercialize Handheld, Point-of-Care Ultrasound Device | What You Should Know: – Exo (pronounced “echo”), a pioneering health information and devices company, announced it has raised $220M in Series C investment round led by RA Capital Management and joined by BlackRock, Sands Capital, Avidity Pa... |